BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Japan

AvenCell Secures Up to $40 Million AMED Grant to Advance Dual-Antigen Allogeneic CAR-T Therapy

AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapie...

July 02, 2025 | News

Alpha Fusion and Curadh Forge Joint Venture to Advance Astatine-211 Radiopharmaceuticals Globally

Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture t...

July 01, 2025 | News

AGC Biologics Launches Cell Therapy Manufacturing Services in Yokohama to Expand Global CDMO Footprint

AGC Biologics, your friendly CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc....

June 26, 2025 | News

Daiichi Sankyo and AstraZeneca’s DATROWAY Receives U.S. FDA Accelerated Approval for EGFR-Mutated Lung Cancer

Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and ...

June 24, 2025 | News

MedHub-AI Secures PMDA Approval in Japan for AutocathFFR®, the World’s First Fully Automated AI-Driven FFR Solution

MedHub-AI, a global leader in AI-powered cardiovascular diagnostics, announced today that the Pharmaceuticals and Medical Devices Agency (PMDA) in&nb...

June 19, 2025 | News

NEC and Chugai Harness AI to Halve Time Needed for Predicting Effective Cancer Drug Combinations

Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% NEC Corporation (NEC; TSE: ...

June 19, 2025 | News

Hoth Therapeutics Secures Japan Patent for HT-KIT Splice-Switching Platform Targeting Mast Cell Disorders

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies, today announced that they have obtained...

June 13, 2025 | News

Samsung Bioepis Partners with NIPRO to Expand Biosimilar Access in Japan

Samsung Bioepis expands its presence in Japanese market through partnership with NIPRO Corporation Marks a step forward in widening treatments options a...

June 09, 2025 | News

FUJIFILM Unifies Life Sciences Brands to Deliver End-to-End Drug Development Solutions

FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences, providing a full spectrum of life sciences solutions built from a 55-year history as a c...

June 04, 2025 | News

Singapore Approves Astellas’ VEOZA™ (Fezolinetant) for Moderate to Severe Menopausal Vasomotor Symptoms

Astellas Singapore has announced that the Health Sciences Authority (HSA) of Singapore has approved VEOZA™ (fezolinetant) 45 mg for the treatment of ...

June 04, 2025 | News

Eisai’s DAYVIGO® Approved in China to Treat Insomnia, Targeting Over 170 Million Adults

Eisai Co., Ltd. announced that the in-house-discovered and developed orexin receptor antagonist DAYVIGO® (generic name: lemborexant) has been app...

May 29, 2025 | News

Fujifilm Validates Cancer-Targeting Potential of Peptide-Oligonucleotide Conjugates Using Proprietary Cyclic Peptide Library

FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation ...

May 21, 2025 | News

RevolKa Secures $1.4M in Series A Extension to Advance AI-Driven Rare Disease Drug Discovery

RevolKa Ltd. (RevolKa), a venture-backed biotech company providing a cutting-edge AI-driven protein engineering technology platform called aiProtein&r...

May 21, 2025 | News

AstraZeneca and Daiichi Sankyo’s ENHERTU Demonstrates Superior pCR in Early HER2+ Breast Cancer in Phase 3 DESTINY-Breast11 Trial

Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastu...

May 08, 2025 | News

Stay Connected